| Measured immunoglobulin E in allergic bronchopulmonary aspergillosis treated with omalizumab. | |
| | |
MedLine Citation:
|
PMID: 20831464 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The ability to assess adequate reductions in immunoglobulin E (IgE) in allergic bronchopulmonary aspergillosis (ABPA) has been a concern with regards to omalizumab treatment. OBJECTIVE: To describe the clinical course and serial measured IgE levels in two adult patients with elevated IgE levels, hypersensitivity to Aspergillus fumigatus, and bilateral bronchiectasis who were treated with omalizumab. CLINICAL DESCRIPTIONS: Patient 1 met commonly used criteria for ABPA and had a more than 3-fold increase (from 702 to 2462 IU/ml) in measured IgE 4 months after starting omalizumab. Two years after starting omalizumab, the IgE level decreased to baseline (473 IU/ml) even when corticosteroids were discontinued. Patient 2 had near normalization of elevated IgE levels when treated with corticosteroids but IgE levels subsequently rose again to over 10,000 IU/ml. After reducing the IgE level to 586 IU/ml with higher corticosteroid doses, omalizumab was initiated. Twenty months after starting omalizumab, the measured IgE was 510 IU/ml. Based on published omalizumab treatment–associated total/free IgE ratios, the estimated free IgE levels for both patients after more than a year of omalizumab treatment was less than their pre–omalizumab treatment IgE levels. CONCLUSIONS: These data suggest that omalizumab can be beneficial in treating ABPA and that measured IgE levels can still be useful in this context. Noting the pattern of IgE levels associated with ABPA exacerbations and with corticosteroid treatment may help both with achieving an IgE level appropriate for omalizumab treatment and with the interpretation of measured IgE changes associated with omalizumab treatment. |
| | |
Authors:
|
Robert Y Lin; Sonali Sethi; Geeta A Bhargave |
Related Documents
:
|
3178314 - Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic f... 2618584 - A possible harmful late effect of methylprednisolone therapy on a time cluster of optic... 11843764 - Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to se... 9408114 - Intravenous immunoglobulin treatment in lower motor neuron disease associated with high... 18959774 - Chloroquine-resistant plasmodium vivax malaria in debre zeit, ethiopia. 1333904 - Treatment of small hepatocellular carcinoma. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: The Journal of asthma : official journal of the Association for the Care of Asthma Volume: 47 ISSN: 1532-4303 ISO Abbreviation: J Asthma Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-10-05 Completed Date: 2010-11-04 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8106454 Medline TA: J Asthma Country: England |
Other Details:
|
Languages: eng Pagination: 942-5 Citation Subset: IM |
Affiliation:
|
Department of Medicine, St Vincent's Hospital–Manhattan–Saint Vincent's Catholic Medical Centers, New York, New York, USA. robert.lin@downtownhospital.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anti-Asthmatic Agents
/
therapeutic use* Antibodies, Monoclonal / therapeutic use* Aspergillosis, Allergic Bronchopulmonary / drug therapy*, immunology* Aspergillus fumigatus / immunology* Bronchiectasis / drug therapy, immunology, microbiology Humans Immunoglobulin E / blood, immunology* Male Middle Aged |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Asthmatic Agents; 0/Antibodies, Monoclonal; 0/omalizumab; 37341-29-0/Immunoglobulin E |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Examining behavioural susceptibility to obesity among Canadian pre-school children: The role of eati...
Next Document: Knowledge, attitude, and self-efficacy in asthma self-management and quality of life.